Wertz Karin K, Pretzlaff Robert K
Department of Pediatrics, University of California, Davis Medical Center, Sacramento, CA, USA.
Pediatr Crit Care Med. 2004 Mar;5(2):181-3. doi: 10.1097/01.pcc.0000113264.00053.af.
To describe the response of a child with persistent fungemia to caspofungin, a member of the echinocandin class of antifungals.
Descriptive case report.
Pediatric intensive care unit at a university teaching hospital.
A 3-yr-old female with persistent candidemia.
After >5 wks of persistent candidemia, caspofungin was added to an antifungal regimen that included amphotericin B and flucytosine.
The addition of caspofungin resulted in rapid clearance of the candidemia. The child recovered without evidence of further fungal infection or overt toxicity.
Caspofungin was administered safely in this pediatric patient and possibly contributed to her clinical improvement. Caspofungin may be considered in children with severe persistent fungal infections that are not responsive to standard therapy. More study in pediatric patients is necessary before recommending its general use.
描述一名患有持续性真菌血症的儿童对棘白菌素类抗真菌药物卡泊芬净的反应。
描述性病例报告。
一所大学教学医院的儿科重症监护病房。
一名3岁持续性念珠菌血症女性患儿。
在持续性念珠菌血症超过5周后，将卡泊芬净添加到包括两性霉素B和氟胞嘧啶的抗真菌治疗方案中。
添加卡泊芬净后念珠菌血症迅速清除。患儿康复，无进一步真菌感染或明显毒性迹象。
卡泊芬净在该儿科患者中使用安全，可能有助于其临床改善。对于对标准治疗无反应的严重持续性真菌感染儿童，可考虑使用卡泊芬净。在推荐其广泛使用之前，有必要对儿科患者进行更多研究。
